Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
990.00
+2.73 (+0.28%)
Streaming Delayed Price
Updated: 1:12 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via
InvestorPlace
Exposures
Product Safety
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
December 11, 2023
Via
Benzinga
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
December 08, 2023
Regeneron has been an excellent investment in recent years. Can that trend continue?
Via
The Motley Fool
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
December 06, 2023
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
11 Analysts Have This to Say About Regeneron Pharmaceuticals
November 28, 2023
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
November 17, 2023
Via
Benzinga
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
December 02, 2023
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
December 01, 2023
Via
Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
November 27, 2023
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.
Via
Talk Markets
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
November 27, 2023
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.
Via
Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
November 27, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...
Via
Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
November 16, 2023
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
November 09, 2023
Via
Benzinga
2 Soaring Stocks to Buy and Hold
November 09, 2023
Both of these companies crushed earnings season.
Via
The Motley Fool
9 Health Care Stocks With Whale Alerts In Today's Session
November 16, 2023
Via
Benzinga
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.
Via
InvestorPlace
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
November 06, 2023
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
Via
Investor's Business Daily
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
November 06, 2023
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during...
Via
Benzinga
Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers
November 02, 2023
The launch of high-dose Eylea is off to a strong start in the U.S.
Via
Investor's Business Daily
Regeneron Pharmaceuticals Unusual Options Activity
November 01, 2023
Via
Benzinga
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review
November 03, 2023
Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than-
Via
Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
November 02, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate
Via
Benzinga
US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple
November 02, 2023
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
November 02, 2023
Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.
Via
The Motley Fool
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
November 01, 2023
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.
Via
Talk Markets
Exposures
COVID-19
Earnings Scheduled For November 2, 2023
November 02, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.